{"pageContent": "Purpose: Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured by activating peripheral blood mononuclear cells, including antigen presenting cells (APCs), with a fusion protein containing prostatic acid phosphatase. Analysis of data from three phase 3 trials was performed to immunologically characterize this therapy during the course of the three doses, and to relate the immunological responses to overall survival (OS).", "metaData": {"source": "Patient Education for Radical Prostatectomy: Development of a Program Tailored to the Needs of Prostate Cancer Patients\nhttps://pubmed.ncbi.nlm.nih.gov/34923862/"}}